Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXYCU for ocular pain in cataract surgery
NCT05550350Phase 3Withdrawn
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
01
Overview
A Phase 3 trial of IBI-10090, sponsored by EyePoint Pharmaceuticals. Planned start Sep 2022; status: withdrawn.
02
Drugs
IBI-10090
Beyond the preview
Go deeper on NCT05550350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05550350.